Business Wire

CA-EXPERIAN

Share
The Sophistication of Cybercriminals Intensifies With Emerging Strategies for Cashing in or Causing Chaos

While tried and true tactics like phishing and malware are here to stay, there are always new approaches to watch out for in the cybersecurity space. Experian’s 11th annual Data Breach Industry Forecast includes six predictions for 2024 that focus a global lens on what savvy moves cybercriminals from near and far will potentially make to penetrate organizations and reap rewards.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240125797127/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

To download the Experian Data Breach Resolution Industry Forecast, go to https://ex.pn/2024databreachindustryforecast. (Graphic: Experian)

While 2023 was a “successful” year for bad actors, we may see the following emerge to shake up the cyber landscape even more this year:

  • Six Degrees of Separation: There’s no question third-party data breaches have made headlines. With increased data collection, storage and movement there are plenty of partners down the supply chain that could be targeted. We predict attacks on systems four, five or six degrees from the original source as vendors outsource data and technology solutions who outsource to another expert and so on.
  • Little by Little Becomes A lot: When trying to achieve a goal, it’s said that taking small steps can lead to big results. Hackers could apply that same rule. Instead of making drastic moves and trying to reap instant reward such as with ransomware, bad actors may just manipulate or alter the tiniest bits of data to stay under the radar such as changing a currency rate or adjusting the coordinates for transportation, which can have a major impact.
  • Not a Third Wheel: It’s widely known who the major players are globally that sponsor attacks and a new country in South Asia may join the international stage with their large population of engineers and programmers. While reportedly having been in the game focusing cyberattacks regionally due to political tensions, this country may broaden their sights in the future.
  • No, not Mother Earth!: Plutonium, terbium, silicon wafers — these rare earth materials that are the building blocks for today’s hardware are rapidly becoming the most sought-after resources on the planet. Any disruption to an already strained supply chain could send the industry (and the economy that relies on these materials) spinning. This presents an intriguing opportunity for hackers looking to create disruption, or nation-states wanting to corner a market or disrupt an enemy’s economy.
  • The Scarface Effect: Like drug cartels, cybergangs are forming sophisticated organizations as joining like-minded actors can be incredibly advantageous. This spans globally with countries potentially helping each other to advance common goals and interests. We’ll see more hackers for trade, crews looking to expand their monopolies, and cyberwarfare alliances.
  • Winning from the Inside: In 2024, we may see enterprising threat actors target more publicly traded companies to gain insights to cheat the stock market or plan their attacks and sell their stash before value nosedives. Rather than breach an organization and play in the underground with stolen data, threat actors could leverage data extraction and their talents in plain sight as everyday investors.

“Cybercriminals are continually working smarter not harder,” said Michael Bruemmer, vice president, Global Data Breach Resolution at Experian. “They are leveraging new technologies like artificial intelligence and applying their talents in different ways to be more strategic and stay a step ahead. Organizations should not ignore even the slightest security abnormalities and be more aware of what global interests may make them a target.”

To access the complimentary report, visit https://ex.pn/2024databreachindustryforecast.

“Today, perpetrators can come from anywhere in the world and bring with them robust resources and expertise,” added Jim Steven, Head of Crisis and Data Response Services at Experian Global Data Breach Resolution in the United Kingdom. “There are many global crime syndicates and nation-backed operations, so companies need to invest in sophisticated prevention and response methods to protect themselves.”

Experian Global Data Breach Resolution offers international resources for companies impacted by a security incident and services include IdentityWorks℠ Global, multilingual call centers, and notifications covering more than 100 countries. Experian has also recently expanded capabilities to Japan, Taiwan and Thailand.

To learn more about Experian Global Data Breach Resolution, go to https://www.experian.com/business/solutions/fraud-management/global-data-breach-services.

About Experian

Experian is the world’s leading global information services company. During life’s big moments – from buying a home or a car, to sending a child to college, to growing a business by connecting with new customers – we empower consumers and our clients to manage their data with confidence. We help individuals to take financial control and access financial services, businesses to make smarter decisions and thrive, lenders to lend more responsibly, and organizations to prevent identity fraud and crime.

We have 22,000 people operating across 32 countries and every day we’re investing in new technologies, talented people, and innovation to help all our clients maximize every opportunity. With corporate headquarters in Dublin, Ireland, we are listed on the London Stock Exchange (EXPN) and are a constituent of the FTSE 100 Index.

Learn more at www.experianplc.com or visit our global content hub at our global news blog for the latest news and insights from the Group.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240125797127/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye